skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Demcizumab (Code C80041)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Demcizumab

Definition: A humanized monoclonal antibody directed against the N-terminal epitope of Notch ligand DLL4 (delta-like 4) with potential antineoplastic activity. Demcizumab binds to the membrane-binding portion of DLL4 and prevents its interaction with Notch-1 and Notch-4 receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may impede tumor angiogenesis. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated into the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium.

Display Name: Demcizumab

Label: Demcizumab

NCI Thesaurus Code: C80041 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2698134  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-Delta-like 4 Monoclonal Antibody OMP-21M18
Anti-DLL4 Monoclonal Antibody OMP-21M18

External Source Codes: 
PDQ Closed Trial Search ID 614677
PDQ Open Trial Search ID 614677 (check for NCI PDQ open clinical trial info)
UMLS CUI C2698134

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula 1243262-17-0
code C80041
Contributing_Source CTRP
Legacy_Concept_Name Anti-DLL4_Monoclonal_Antibody_OMP-21M18
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom